Caris Life Sciences director exercises, sells 400K shares

Caris Life Sciences, Inc. (CAI) director and officer Brian J. Brille reported an exercise of 400,000 stock options at an exercise price of $2.44 per share on September 17, 2026, receiving 400,000 shares of common stock.

Rhea-AI Filing Summary

Caris Life Sciences, Inc. (CAI) director and officer Brian J. Brille reported an exercise of 400,000 stock options at an exercise price of $2.44 per share on September 17, 2026, receiving 400,000 shares of common stock. On the same date, he sold 400,000 common shares at a weighted average price of $30.3302 per share, with individual sale prices ranging from $30.21 to $30.565. Following the option exercise, he directly holds 1,600,000 stock options, and 500,000 common shares are held indirectly through a family trust for which beneficial ownership is disclaimed except to the extent of his pecuniary interest.

Insider Trade Summary

Exercise and Sale: 400,000 shares ($11.16M approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Brille Brian J

Role See Remarks

Sold 400,000 shs ($12.13M)

Approx. gross sale proceeds $12.13M

Approx. exercise cost $976K

Approx. pre-tax spread $11.16M

Type	Security	Shares	Price	Value
Exercise	Stock Option F4	400,000	$0.00	$0.00
Exercise	Common Stock	400,000	$2.44	$976K
Sale	Common Stock F1	400,000	$30.3302	$12.13M
holding	Common Stock F2, F3	--	--	--

Holdings After Transaction: Stock Option — 1,600,000 contracts (Direct); Common Stock — 230,303 shares (Direct); Common Stock — 500,000 shares (Indirect, By Trust)

Footnotes (4)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.2100 to $30.5650, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. F2. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
3. F3. By a family trust, with shares previously held in multiple family trusts consolidated into a single trust.
4. F4. The stock option is fully vested and exercisable.

Key Figures

Options exercised: 400,000 shares Option exercise price: $2.44 per share Shares sold: 400,000 shares +4 more

7 metrics

Options exercised 400,000 shares Stock options exercised into common stock on September 17, 2026

Option exercise price $2.44 per share Exercise price of stock options converted into 400,000 common shares

Shares sold 400,000 shares Common stock sold on September 17, 2026

Weighted average sale price $30.3302 per share Weighted average of multiple sale transactions between $30.21 and $30.565

Options held after transaction 1,600,000 options Total direct stock options reported as held after the exercise

Indirect trust holdings 500,000 shares Common shares held by a family trust with disclaimed beneficial ownership

Option expiration date January 14, 2028 Expiration date of the fully vested, exercisable stock option

Key Terms

weighted average price, beneficial ownership, pecuniary interest, family trust, +1 more

5 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein."

family trust financial

"By a family trust, with shares previously held in multiple family trusts consolidated into a single trust."

fully vested and exercisable financial

"The stock option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CAI’s Brian J. Brille report on September 17, 2026?

Brian J. Brille exercised 400,000 stock options at $2.44 per share, acquiring 400,000 common shares, and on the same day sold 400,000 common shares at a weighted average price of $30.3302 per share, with sales between $30.21 and $30.565.

At what prices were the CAI shares sold in Brian J. Brille’s Form 4?

The 400,000 CAI common shares were sold at a weighted average price of $30.3302 per share. According to the disclosure, the sales occurred in multiple transactions at prices ranging from $30.21 to $30.565 per share.

How many CAI stock options does Brian J. Brille hold after these transactions?

After the reported transactions, Brian J. Brille directly holds 1,600,000 stock options of Caris Life Sciences, Inc. The reported option involved in this Form 4 is fully vested and exercisable and expires on January 14, 2028.

What indirect CAI share holdings are reported for Brian J. Brille?

An indirect holding of 500,000 CAI common shares is reported as held by a family trust, with shares previously in multiple family trusts consolidated into one. Brille disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Was a Rule 10b5-1 trading plan indicated for Brian J. Brille’s CAI transactions?

No. The filing indicates that the Rule 10b5-1 checkbox is not selected, and the footnotes do not state that the transactions were executed pursuant to a Rule 10b5-1 trading plan.

What is the exercise price and expiration date of the CAI options Brille exercised?

The exercised stock options for CAI common stock have an exercise price of $2.44 per share. The option is reported as fully vested and exercisable and carries an expiration date of January 14, 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 06:08 PM Accepted by SEC EDGAR 09/17/2026 - 06:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brille Brian J

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TEXAS 75039

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2026		M		400,000	A	$2.44	630,303	D
Common Stock	09/17/2026		S		400,000	D	$30.3302(1)	230,303	D
Common Stock								500,000	I	By Trust(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$2.44	09/17/2026		M			400,000	(4)	01/14/2028	Common Stock	400,000	$0	1,600,000	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.2100 to $30.5650, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

3. By a family trust, with shares previously held in multiple family trusts consolidated into a single trust.

4. The stock option is fully vested and exercisable.

Remarks:

Vice Chairman and Executive Vice President

	/s/ J. Russel Denton, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)